看多
CGI Triple Bottom
Hello,
What is CGI?
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
News
My Thoughts For You
Currently, we have a double bottom but started a retracement once the RSI was showing overbought conditions, which is why I suspect a retracement making it a triple bottom. There is a slight chance that we won't see a triple bottom which makes this pattern a double bottom but the outcome is still the same regarding the target.
This stock IMO is not worth getting into because many lost 99% of their investment since the stock's conception. Additionally, the pattern says bullish but this may not happen regarding the historical price action.
If you're not sure how to get into a trade or when to take profits then check out this tutorial I have created in the comments section under "My Trade Advice For You"
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
What is CGI?
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
News
My Thoughts For You
Currently, we have a double bottom but started a retracement once the RSI was showing overbought conditions, which is why I suspect a retracement making it a triple bottom. There is a slight chance that we won't see a triple bottom which makes this pattern a double bottom but the outcome is still the same regarding the target.
This stock IMO is not worth getting into because many lost 99% of their investment since the stock's conception. Additionally, the pattern says bullish but this may not happen regarding the historical price action.
If you're not sure how to get into a trade or when to take profits then check out this tutorial I have created in the comments section under "My Trade Advice For You"
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
相關出版品
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。